- Transferrin-Conjugated Nanoparticles of Poly(Lactide)-D-α-Tocopheryl Polyethylene Glycol Succinate Diblock Copolymer for Targeted Drug Delivery across the Blood–Brain Barrier

2014 ◽  
pp. 826-849
Keyword(s):  
Drug Delivery ◽  
Polyethylene Glycol ◽  
Blood Brain Barrier ◽  
Diblock Copolymer ◽  
Targeted Drug Delivery ◽  
Brain Barrier ◽  
Glycol Succinate ◽  
Blood Brain ◽  
Targeted Drug

Recent Advances in Targeted Drug Delivery Approaches using Lipidic and Polymeric Nanocarriers for the management of Alzheimer’s Disease

2021 ◽  
Vol 27 ◽  
Author(s):  
Dhara Lakdawala ◽  
Md Abdur Rashid ◽  
Farhan Jalees Ahmad
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Blood Brain Barrier ◽  
Targeted Drug Delivery ◽  
Brain Barrier ◽  
Polymeric Nanocarriers ◽  
Blood Brain ◽  
Targeted Drug ◽  
The Brain

: Drug delivery to the brain has remained a significant challenge in treating neurodegenerative disorders such as Alzheimer's disease due to the presence of the blood-brain barrier, which primarily obstructs the access of drugs and biomolecules into the brain. Several methods to overcome the blood-brain barrier have been employed, such as chemical disruption, surgical intervention, focused ultrasound, intranasal delivery and using nanocarriers. Nanocarrier systems remain the method of choice and have shown promising results over the past decade to achieve better drug targeting. Polymeric nanocarriers and lipidic nanoparticles act as a carrier system providing better encapsulation of drugs, site-specific delivery, increased bioavailability and sustained release of drugs. The surface modifications and functionalization of these nanocarrier systems have greatly facilitated targeted drug delivery. The safety and efficacy of these nanocarrier systems have been ascertained by several in vitro and in vivo models. In the present review, we have elaborated on recent developments of nanoparticles as a drug delivery system for Alzheimer's disease, explicitly focusing on polymeric and lipidic nanoparticles.

GDNF fusion protein for targeted-drug delivery across the human blood–brain barrier

2008 ◽  
Vol 100 (2) ◽  
pp. 387-396 ◽  
Author(s):  
Ruben J. Boado ◽  
Yun Zhang ◽  
Yufeng Zhang ◽  
Yuntao Wang ◽  
William M. Pardridge
Keyword(s):  
Drug Delivery ◽  
Fusion Protein ◽  
Blood Brain Barrier ◽  
Human Blood ◽  
Targeted Drug Delivery ◽  
Brain Barrier ◽  
Blood Brain ◽  
Targeted Drug

Efficacy of Dual-Targeting Combined Anti-Tuberculosis Drug Delivery System in the Treatment of Tuberculous Meningitis

2021 ◽  
Vol 17 (10) ◽  
pp. 2034-2042
Author(s):  
Wenjing Ma ◽  
Huan Peng ◽  
Kewei Liu ◽  
Yaguo Wang ◽  
Wei Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mycobacterium Tuberculosis ◽  
Drug Delivery System ◽  
Blood Brain Barrier ◽  
Delivery System ◽  
Tuberculous Meningitis ◽  
Targeted Drug Delivery ◽  
Brain Barrier ◽  
Blood Brain ◽  
Targeted Drug

Tuberculous meningitis (TBM) is an incurable disease with high mortality. It is an extrapulmonary tuberculosis caused by mycobacterium tuberculosis which penetrated the blood-brain barrier and infected the meninges. Mycobacterium tuberculosis lurking in the body mainly reside in macrophages. Anti-tuberculous drugs usually can not target the blood-brain barrier and macrophages, the drug concentration in the lesion is low, which cannot effectively kill mycobacterium tuberculosis, making TBM difficult to treat. Targeted drug delivery systems can target drugs to specific nidus. In the study, we constructed a drug delivery system, which was a cell penetrate peptide B6 and phosphatidylserine (PS) modified polyethylene glycol (PEG) nanomaterial to target the blood-brain barrier and to target macrophages. This nanomaterial was a combined anti-tuberculosis drug delivery system encapsulating antituberculosis drugs rifampicin and pyrazinamide, designed to target macrophages in the brain and kill mycobacterium tuberculosis lurking in the macrophages. We have physically characterized the drug delivery system, and verified the bactericidal ability at cellular and animal level. Results have shown that the targeted drug delivery system had a remarkable efficacy to treat TBM in mice.

scholarly journals IgG-Paraoxonase-1 Fusion Protein for Targeted Drug Delivery across the Human Blood−Brain Barrier

2008 ◽  
Vol 5 (6) ◽  
pp. 1037-1043 ◽  
Author(s):  
Ruben J. Boado ◽  
Yun Zhang ◽  
Yufeng Zhang ◽  
Yuntao Wang ◽  
William M. Pardridge
Keyword(s):  
Drug Delivery ◽  
Fusion Protein ◽  
Blood Brain Barrier ◽  
Human Blood ◽  
Targeted Drug Delivery ◽  
Brain Barrier ◽  
Paraoxonase 1 ◽  
Blood Brain ◽  
Targeted Drug
Sign in / Sign up

Export Citation Format

Share Document